The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Open accessAbstract
BACKGROUND CLDN18.2 is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, mediates specific killing of CLDN18.2-positive cells through immune effector mechanisms. PATIENTS AND METHODS The FAST study enrolled advanced gastric/gastro-oesophageal junction (G/GEJ) and oesophageal adenocarcinoma (EC) patients (≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells. Patients received first-line epirubicin+oxaliplatin+capecitabine (EOX, Arm 1, n=84) every 3 weeks (Q3W), or zolbetuximab+EOX (loading dose, 800 mg/m2 then 600 mg/m2 Q3W) (Arm 2, n=77). Arm 3 (exploratory) was added post-enrollment initiation (zolbetuximab+EOX 1000 mg/m2 Q3W, n=85). Primary endpoint was progression-free survival (PFS) and overall survival (OS) was a secondary endpoint RESULTS: In the overall population, both PFS (HR=0.44; 95% CI, 0.29-0.67; P<0.0005) and OS (HR=0.55; 95% CI, 0.39-0.77; P<0.0005) were significantly improved with zolbetuximab+EOX (Arm 2) compared with EOX alone (Arm 1). This significant PFS benefit was retained in patients with moderate-to-strong CLDN18.2 expression in ≥70% of tumour cells (HR=0.38; 95% CI, 0.23-0.62; P<0.0005). Significant improvement in PFS was also reported in the overall population of Arm 3 vs Arm 1 (HR=0.58; 95% CI, 0.39-0.85; P=0.0114) but not in high CLDN18.2-expressing patients; no significant improvement in OS was observed in either population. Most adverse events (AEs) related to zolbetuximab+EOX (nausea, vomiting, neutropaenia, anaemia) were grade 1-2. Grade ≥3 AEs showed no substantial increases overall (zolbetuximab+EOX vs EOX alone). CONCLUSIONS In advanced G/GEJ and EC patients expressing CLDN18.2, adding zolbetuximab to first-line EOX provided longer PFS and OS vs EOX alone. Zolbetuximab+EOX was generally tolerated and AEs were manageable. Zolbetuximab 800/600 mg/m2 is being evaluated in phase III studies based on clinical benefit observed in the overall population and in patients with moderate-to-strong CLDN18.2 expression in ≥70% of tumour cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Self-citationCapecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Smyth, E. C., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw350 · Cited by 1,555
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Okines, A., Verheij, M., Allum, W., Cunningham, D., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq164 · Cited by 1,300
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Progress in the treatment of advanced gastric cancer
Song, Z., Wu, Y., Yang, J., Yang, D., & Fang, X. (2017) · Tumor Biology · doi:10.1177/1010428317714626 · Cited by 924
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
Sahin, U., Koslowski, M., Dhaene, K., Usener, D., Brandenburg, G., Seitz, G., Huber, C., & Türeci, O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1547 · Cited by 501
Self-citationNiimi, T., Nagashima, K., Ward, J. M., Minoo, P., Zimonjic, D. B., Popescu, N. C., & Kimura, S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7380-7390.2001 · Cited by 291
Türeci, O., Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., Thuss-Patience, P., Ettrich, T., Arnold, D., Bassermann, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz199 · Cited by 248
Self-citationAnti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
Singh, P., Toom, S., & Huang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0473-4 · Cited by 224
The role of molecular remodeling in differential regulation of tight junction permeability
Turner, J. R., Buschmann, M. M., Romero-Calvo, I., Sailer, A., & Shen, L. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.09.022 · Cited by 200
Sahin, U., Schuler, M., Richly, H., Bauer, S., Krilova, A., Dechow, T., Jerling, M., Utsch, M., Rohde, C., Dhaene, K., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.007 · Cited by 168
Self-citationThe claudin family of proteins in human malignancy: a clinical perspective
Chen, Y., Ding, L., Lü, Z., & Lu, Q. (2013) · Cancer Management and Research · doi:10.2147/cmar.s38294 · Cited by 148
Characterization of zolbetuximab in pancreatic cancer models
Türeci, Ö., Mitnacht‐Kraus, R., Wöll, S., Yamada, T., & Şahin, U. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1523096 · Cited by 134
Self-citationRegulation of paracellular permeability: factors and mechanisms
Hu, Y.-J., Wang, Y., Tan, F.-Q., & Yang, W. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2724-y · Cited by 129
Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals
Türeci, Ö., Koslowski, M., Helftenbein, G., Castle, J. C., Rohde, C., Dhaene, K., Seitz, G., & Şahin, U. (2011) · Gene · doi:10.1016/j.gene.2011.04.007 · Cited by 128
Self-citationExpression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer
Jun, K., Kim, J.-H., Jung, J., Choi, H., & Chin, H.-M. (2013) · International Journal of Surgery · doi:10.1016/j.ijsu.2013.11.022 · Cited by 107
Sentani, K., Oue, N., Tashiro, T., Sakamoto, N., Nishisaka, T., Fukuhara, T., Taniyama, K., Matsuura, H., Arihiro, K., Ochiai, A., et al. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318163a8f8 · Cited by 71
Late-line treatment in metastatic gastric cancer: today and tomorrow
Smyth, E. C., & Moehler, M. H. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919867522 · Cited by 57
Moentenich, V., Gebauer, F., Çomut, E., Tuchscherer, A., Bruns, C. J., Schroeder, W., Buettner, R., Alakus, H., Loeser, H., Zander, T., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11520 · Cited by 50
Xu, R.-H., Ajani, J. A., Al-Batran, S.-E., Bang, Y.-J., Catenacci, D. V. T., Enzinger, P. C., Ilson, D. H., Kim, S., Lordick, F., Shitara, K., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.459 · Cited by 5
Self-citation
Cited by
Gastric cancer treatment: recent progress and future perspectives
Guan, W.-L., He, Y., & Xu, R.-H. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01451-3 · Cited by 944
Shitara, K., Lordick, F., Bang, Y.-J., Enzinger, P., Ilson, D., Shah, M. A., Van Cutsem, E., Xu, R.-H., Aprile, G., Xu, J., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00620-7 · Cited by 822
Self-citationShah, M. A., Shitara, K., Ajani, J. A., Bang, Y.-J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., Gallego Plazas, J., Huang, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02465-7 · Cited by 681
Self-citationClaudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., Zhang, M., Peng, Z., Zhou, J., Cao, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01800-8 · Cited by 604
Current developments in gastric cancer: from molecular profiling to treatment strategy
Alsina, M., Arrazubi, V., Diez, M., & Tabernero, J. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00703-w · Cited by 350
Metadata
- Authors
- Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., Vynnychenko, I., Dudov, A., Bazin, I., Bondarenko, I., Melichar, B., Dhaene, K., Wiechen, K., Huber, C., Maurus, D., Arozullah, A., Park, J. W., Schuler, M., & Al-Batran, S.-E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 32
- Issue
- 5
- Pages
- 609-619
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3132443161
- Cited by
- 383
- References
- 22
- FWCI
- 36.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.